IP Library Granted Patent US 9,539,229
Granted Patent B2
US 9,539,229 · App. 14/768,183 · Granted Jan 10, 2017

Intestinal tract-protecting agent containing hydroxylated fatty acid

Inventors: Jun Ogawa (Kyoto, JP); Shigenobu Kishino (Kyoto, JP); Yasunori Yonejima (Muko, JP)
Assignees: Kyoto University; Nitto Pharmaceutical Industries, Ltd.
A61K31/201A23K20/158A23L33/12C07C59/42A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,539,229
App. No.
14/768,183
Granted
Jan 10, 2017
Kind
B2
Abstract

The present invention provides an intestinal tract-protecting agent, an agent for the prophylaxis or improvement of a disease caused by damage in intestinal tract barrier function, which contains hydroxylated fatty acid, particularly hydroxylated unsaturated fatty acid, having a hydroxyl group at the 10-position and/or the 12-position, which is an intermediate of the metabolism of unsaturated fatty acid by lactobacillus.

Claims (8)

1. A method for the prophylaxis or treatment of damage in intestinal tract barrier function or a disease caused by the damage in a mammal, comprising administering an effective amount of a hydroxlyated fatty acid having 18 carbon atoms and having a hydroxyl group at the 10-position to the mammal, thereby treating or preventing damage in intestinal tract barrier function or a disease caused by the damage.

2. The method according to claim 1 , wherein the disease caused by damage in intestinal tract barrier function is at least one kind of disease selected from the group consisting of inflammatory bowel disease, ulcer and irritable bowel syndrome.

3. The method according to claim 1 , wherein the hydroxylated fatty acid is a hydroxylated unsaturated fatty acid.

4. The method according to claim 3 , wherein the disease caused by damage in intestinal tract barrier function is at least one kind of disease selected from the group consisting of inflammatory bowel disease, ulcer and irritable bowel syndrome.

5. The method according to claim 3 , wherein the hydroxylated unsaturated fatty acid has a cis double bond at the 12-position.

6. The method according to claim 5 , wherein the disease caused by damage in intestinal tract barrier function is at least one kind of disease selected from the group consisting of inflammatory bowel disease, ulcer and irritable bowel syndrome.

7. The method according to claim 3 , wherein the hydroxylated unsaturated fatty acid is 10-hydroxy-cis-12-octadecenoic acid.

8. The method according to claim 7 , wherein the disease caused by damage in intestinal tract barrier function is at least one kind of disease selected from the group consisting of inflammatory bowel disease, ulcer and irritable bowel syndrome.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE PROPERTY TYPE FROM APPLICATION NUMBER TO PATENT NUMBER FOR 10952983 AND 10975397 PREVIOUSLY RECORDED AT REEL: 68851 FRAME: 663. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 18, 2024
From: KYOTO UNIVERSITY
To: NOSTER INC.
Reel/Frame 069207/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2024
From: KYOTO UNIVERSITY
To: NOSTER INC.
Reel/Frame 068851/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2021
From: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
To: NOSTER INC.
Reel/Frame 055920/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2015
From: OGAWA, JUN; KISHINO, SHIGENOBU; YONEJIMA, YASUNORI
To: KYOTO UNIVERSITY; NITTO PHARMACEUTICAL INDUSTRIES, LTD.
Reel/Frame 036333/0157 →
Priority Claims (1)
JP 2013-031769 · Feb 21, 2013 · national
Continuity (1)
Related Publication 20160000739A1 · Jan 7, 2016